A robust method for the assessment of average bioequivalence in the presence of outliers and skewness.

PURPOSE: In this paper, we propose a robust Bayesian method for the assessment of average bioequivalence based on data from conventional crossover studies. We evaluate and motivate empirically the need for robust methods in bioequivalence studies by comparing the results of robust and conventional statistical methods in a large data pool of bioequivalence studies. METHODS: Robustness of the statistical methodology is achieved by replacing the normal distributions for residuals in the linear mixed model with skew-t distributions. In this way, the statistical model can accommodate skew and heavy-tailed data, particularly outliers, yielding robust statistical inference without the need for excluding outliers from the analysis. We performed a simulation study to investigate and compare the performance of the robust and conventional models. RESULTS: Our study shows that in some trials, the distribution of residuals is skew and heavy-tailed. In the presence of outliers, the 90% confidence intervals for the ratio of geometric means tend to be narrower for the robust methods than for the conventional method. Our simulation study shows that the robust method has suitable frequentist properties and yields more precise confidence intervals and higher statistical power than the conventional maximum likelihood method when outliers are present in the data. CONCLUSIONS: As a sensitivity analysis, we recommend the fit of robust models for handling outliers that are occasionally encountered in crossover design bioequivalence data.

A robust Bayesian mixed effects approach for zero inflated and highly skewed longitudinal count data emanating from the zero inflated discrete Weibull distribution.

This article proposes a Bayesian mixed effects zero inflated discrete Weibull (ZIDW) regression model for zero inflated and highly skewed longitudinal count data, as an alternative to mixed effects regression models that are based on the negative binomial, zero inflated negative binomial, and conventional discrete Weibull (DW) distributions. The mixed effects ZIDW regression model is an extension of a recently introduced model based on the DW distribution and uses the log-link function to specify the relationship between the linear predictors and the median counts. The ZIDW approach offers a more robust characteristic of central tendency, compared to the mean count, when there is skewness in the data. A matrix generalized half-t (MGH-t) prior distribution is specified for the random effects covariance matrix as an alternative to the widely used Wishart prior distribution. The methodology is applied to a longitudinal dataset from an epilepsy clinical trial. In a data contamination simulation study, we show that the mixed effect ZIDW regression model is more robust than the competing mixed effects regression models when the data contain excess zeros or outliers. The performance of the ZIDW regression model is also assessed in a simulation study under the specification of, respectively, the MGH-t and Wishart prior distributions for the random effects covariance matrix. It turns out that the highest posterior density intervals under the MGH-t prior for the fixed effects maintain nominal coverage when the true variability between random slopes over time is small, whereas those under the Wishart prior are generally conservative.

A generalized Bayesian nonlinear mixed-effects regression model for zero-inflated longitudinal count data in tuberculosis trials.

In this paper, we investigate Bayesian generalized nonlinear mixed-effects (NLME) regression models for zero-inflated longitudinal count data. The methodology is motivated by and applied to colony forming unit (CFU) counts in extended bactericidal activity tuberculosis (TB) trials. Furthermore, for model comparisons, we present a generalized method for calculating the marginal likelihoods required to determine Bayes factors. A simulation study shows that the proposed zero-inflated negative binomial regression model has good accuracy, precision, and credibility interval coverage. In contrast, conventional normal NLME regression models applied to log-transformed count data, which handle zero counts as left censored values, may yield credibility intervals that undercover the true bactericidal activity of anti-TB drugs. We therefore recommend that zero-inflated NLME regression models should be fitted to CFU count on the original scale, as an alternative to conventional normal NLME regression models on the logarithmic scale.

Robust fit of Bayesian mixed effects regression models with application to colony forming unit count in tuberculosis research.

Early bactericidal activity of tuberculosis drugs is conventionally assessed using statistical regression modeling of colony forming unit (CFU) counts over time. Typically, most CFU counts deviate little from the regression curve, but gross outliers due to erroneous sputum sampling are occasionally present and can markedly influence estimates of the rate of change in CFU count, which is the parameter of interest. A recently introduced Bayesian nonlinear mixed effects regression model was adapted to offer a robust approach that accommodates both outliers and potential skewness in the data. At its most general, the proposed regression model fits the skew Student t distribution to residuals and random coefficients. Deviance information criterion statistics and compound Laplace-Metropolis marginal likelihoods were used to discriminate between alternative Bayesian nonlinear mixed effects regression models. We present a relatively easy method to calculate the marginal likelihoods required to determine compound Laplace-Metropolis marginal likelihoods, by adapting methods available in currently available statistical software. The robust methodology proposed in this paper was applied to data from 6 clinical trials. The results provide strong evidence that the distribution of CFU count is often heavy tailed and negatively skewed (suggesting the presence of outliers). Therefore, we recommend that robust regression models, such as those proposed here, should be fitted to CFU count.

Robust Bayesian nonlinear mixed-effects modeling of time to positivity in tuberculosis trials.

Early phase 2 tuberculosis (TB) trials are conducted to characterize the early bactericidal activity (EBA) of anti-TB drugs. The EBA of anti-TB drugs has conventionally been calculated as the rate of decline in colony forming unit (CFU) count during the first 14 days of treatment. The measurement of CFU count, however, is expensive and prone to contamination. Alternatively to CFU count, time to positivity (TTP), which is a potential biomarker for long-term efficacy of anti-TB drugs, can be used to characterize EBA. The current Bayesian nonlinear mixed-effects (NLME) regression model for TTP data, however, lacks robustness to gross outliers that often are present in the data. The conventional way of handling such outliers involves their identification by visual inspection and subsequent exclusion from the analysis. However, this process can be questioned because of its subjective nature. For this reason, we fitted robust versions of the Bayesian nonlinear mixed-effects regression model to a wide range of TTP datasets. The performance of the explored models was assessed through model comparison statistics and a simulation study. We conclude that fitting a robust model to TTP data obviates the need for explicit identification and subsequent "deletion" of outliers but ensures that gross outliers exert no undue influence on model fits. We recommend that the current practice of fitting conventional normal theory models be abandoned in favor of fitting robust models to TTP data.

A Bayesian Nonlinear Mixed-Effects Regression Model for the Characterization of Early Bactericidal Activity of Tuberculosis Drugs.

Trials of the early bactericidal activity (EBA) of tuberculosis (TB) treatments assess the decline, during the first few days to weeks of treatment, in colony forming unit (CFU) count of Mycobacterium tuberculosis in the sputum of patients with smear-microscopy-positive pulmonary TB. Profiles over time of CFU data have conventionally been modeled using linear, bilinear, or bi-exponential regression. We propose a new biphasic nonlinear regression model for CFU data that comprises linear and bilinear regression models as special cases and is more flexible than bi-exponential regression models. A Bayesian nonlinear mixed-effects (NLME) regression model is fitted jointly to the data of all patients from a trial, and statistical inference about the mean EBA of TB treatments is based on the Bayesian NLME regression model. The posterior predictive distribution of relevant slope parameters of the Bayesian NLME regression model provides insight into the nature of the EBA of TB treatments; specifically, the posterior predictive distribution allows one to judge whether treatments are associated with monolinear or bilinear decline of log(CFU) count, and whether CFU count initially decreases fast, followed by a slower rate of decrease, or vice versa.